MCID: THY124
MIFTS: 54

Thyroid Gland Papillary Carcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Thyroid Gland Papillary Carcinoma

MalaCards integrated aliases for Thyroid Gland Papillary Carcinoma:

Name: Thyroid Gland Papillary Carcinoma 12
Papillary Carcinoma of the Thyroid Gland 12
Papillary Thyroid Carcinoma 15

Classifications:



External Ids:

Disease Ontology 12 DOID:3969
MeSH 44 C536915
NCIt 50 C4035
SNOMED-CT 68 4797003
UMLS 72 C0238463

Summaries for Thyroid Gland Papillary Carcinoma

Disease Ontology : 12 A differentiated thyroid gland carcinoma that is characterized by the small mushroom shape of the tumor which has a stem attached to the epithelial layer abd arises from the follicular cells of the thyroid gland.

MalaCards based summary : Thyroid Gland Papillary Carcinoma, also known as papillary carcinoma of the thyroid gland, is related to nodular goiter and thyroiditis. An important gene associated with Thyroid Gland Papillary Carcinoma is MIR222 (MicroRNA 222), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Iodine and Trace Elements have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and breast, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Related Diseases for Thyroid Gland Papillary Carcinoma

Diseases related to Thyroid Gland Papillary Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 435)
# Related Disease Score Top Affiliating Genes
1 nodular goiter 31.6 TSHR TG RET LGALS3
2 thyroiditis 31.3 TSHR TG RET
3 papillary thyroid microcarcinoma 31.2 TSHR TG NKX2-1 BRAF
4 ovarian germ cell teratoma 31.1 TG RET NKX2-1
5 mature teratoma 31.0 TG BRAF
6 struma ovarii 30.9 TSHR TG RET NKX2-1 BRAF
7 colloid adenoma 30.8 TG NKX2-1 LGALS3
8 benign struma ovarii 30.8 TSHR TG RET
9 thyroid carcinoma, familial medullary 30.7 TG RET NKX2-1
10 hashimoto thyroiditis 30.7 TSHR TG RET LGALS3 KRT19 BRAF
11 goiter 30.5 TSHR TG PAX8 NKX2-1 LGALS3
12 graves disease 1 30.5 TSHR TG
13 endemic goiter 30.5 TSHR TG
14 postsurgical hypothyroidism 30.4 TSHR TG
15 endocrine gland cancer 30.3 TG RET PAX8 KRT19
16 multinodular goiter 30.3 TSHR TG PAX8 NKX2-1
17 congenital hypothyroidism 30.2 TSHR TG PAX8 NKX2-1
18 nontoxic goiter 30.1 TSHR TG
19 hypothyroidism 30.0 TSHR TG RET PAX8 NKX2-1
20 thyroid cancer, nonmedullary, 2 29.9 TSHR TG RET PAX8 NKX2-1 LGALS3
21 glioma 29.6 PTCSC3 MIR222 MIR221 MIR146B BRAF
22 malignant struma ovarii 29.5 TG RET PTCH1 NKX2-1 NCOA4 LGALS3
23 papillary carcinoma 29.2 TSHR TG RET PAX8 NKX2-1 NCOA4
24 follicular adenoma 29.2 TSHR TG RET PAX8 NKX2-1 LGALS3
25 differentiated thyroid carcinoma 28.8 TSHR TG RET PAX8 NKX2-1 NCOA4
26 thyroid cancer, nonmedullary, 1 28.8 PTCSC3 NKX2-1 NCOA4 MIR222 MIR221 MIR146B
27 thyroid gland disease 28.3 TSHR TPCN1 TG RET PTCH1 PAX8
28 thyroid carcinoma, papillary, with papillary renal neoplasia 11.7
29 multicentric papillary thyroid carcinoma 11.5
30 columnar cell variant papillary carcinoma 11.5
31 tall cell variant papillary carcinoma 11.5
32 thyroid cancer, nonmedullary, 4 11.4
33 thyroid gland cancer 10.8
34 familial adenomatous polyposis 10.7
35 thyroid gland follicular carcinoma 10.7
36 graves' disease 10.6
37 hyperparathyroidism 10.6
38 thyroid gland anaplastic carcinoma 10.6
39 basal cell carcinoma, multiple 10.6 PTCH2 PTCH1
40 parathyroid adenoma 10.6
41 water-clear cell adenoma 10.6 TG PAX8
42 primary hyperparathyroidism 10.6
43 polymyositis 10.5 MIR222 MIR146B
44 squamous cell carcinoma 10.5
45 teratoma 10.5
46 ovarian germ cell cancer 10.5 TG RET NKX2-1
47 neonatal thyrotoxicosis 10.5 TSHR PAX8
48 fetal adenoma 10.4 TG NKX2-1 LGALS3
49 toxic diffuse goiter 10.4 TSHR TG C6orf15
50 breast cancer 10.4

Graphical network of the top 20 diseases related to Thyroid Gland Papillary Carcinoma:



Diseases related to Thyroid Gland Papillary Carcinoma

Symptoms & Phenotypes for Thyroid Gland Papillary Carcinoma

MGI Mouse Phenotypes related to Thyroid Gland Papillary Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.03 BRAF KRT19 LGALS3 NKX2-1 PTCH1 PTCH2
2 endocrine/exocrine gland MP:0005379 10.01 BRAF KRT19 NKX2-1 PAX8 PTCH1 RET
3 nervous system MP:0003631 9.96 BRAF KRT19 LGALS3 NKX2-1 PAX8 PTCH1
4 neoplasm MP:0002006 9.92 BRAF KRT19 LGALS3 NKX2-1 PTCH1 PTCH2
5 limbs/digits/tail MP:0005371 9.85 BRAF PAX8 PTCH1 RET TG TSHR
6 normal MP:0002873 9.76 BRAF KRT19 NKX2-1 PAX8 PTCH1 PTCH2
7 reproductive system MP:0005389 9.61 BRAF KRT19 LGALS3 NKX2-1 PAX8 PTCH1
8 skeleton MP:0005390 9.23 BRAF KRT19 LGALS3 NKX2-1 PAX8 PTCH1

Drugs & Therapeutics for Thyroid Gland Papillary Carcinoma

Drugs for Thyroid Gland Papillary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 2, Phase 3 7553-56-2 807
2 Trace Elements Phase 2, Phase 3
3 Micronutrients Phase 2, Phase 3
4 Nutrients Phase 2, Phase 3
5 Anti-Infective Agents, Local Phase 2, Phase 3
6 Anti-Infective Agents Phase 2, Phase 3
7 cadexomer iodine Phase 2, Phase 3
8
Calcium carbonate Approved, Investigational Phase 2 471-34-1
9
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
10
Pembrolizumab Approved Phase 2 1374853-91-4
11
Lenvatinib Approved, Investigational Phase 2 417716-92-8
12
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
13
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
14
Alfacalcidol Approved, Nutraceutical Phase 2 41294-56-8 5282181
15
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
16
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
17
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
18 Liver Extracts Phase 2
19 Antacids Phase 2
20 Hormones Phase 2
21 Vitamin D2 Phase 2
22 Gastrointestinal Agents Phase 2
23 Vitamins Phase 2
24 Ergocalciferols Phase 2
25 Hydroxycholecalciferols Phase 2
26 Calciferol Phase 2
27 Calcium, Dietary Phase 2
28 Anti-Ulcer Agents Phase 2
29 Bone Density Conservation Agents Phase 2
30 Antineoplastic Agents, Immunological Phase 2
31 Protein Kinase Inhibitors Phase 2
32 Fluorodeoxyglucose F18 Phase 2
33 Radiopharmaceuticals Phase 2
34
Dabrafenib Approved, Investigational Phase 1 1195765-45-7 44462760 44516822
35 Anti-Inflammatory Agents
36 Anesthetics

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma: A Prospective Randomized Controlled Trial Completed NCT00795782 Phase 3
2 Value of Sentinel Lymph Node Biopsy to Lateral Neck Lymph Node in Thyroid Carcinoma: Prospective Study Completed NCT01137097 Phase 2, Phase 3
3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy Recruiting NCT03690388 Phase 3 Cabozantinib;Placebo
4 Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
5 ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer Not yet recruiting NCT03570021 Phase 3
6 A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma Completed NCT01502410 Phase 2 sorafenib tosylate
7 Phase 2 Study of Routine Oral Calcium and Vitamine D Supplements to Prevent Hypocalcemia After Total Thyroidectomy in Papillary Thyroid Carcinoma Patients Completed NCT00630214 Phase 2
8 Phase 2 Study of Selumetinib Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements Completed NCT00559949 Phase 2 Selumetinib
9 A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma Completed NCT00104871 Phase 2 Bortezomib
10 Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy Completed NCT01811212 Phase 2 Cabozantinib S-malate
11 A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma Completed NCT01813136 Phase 2 Continuous pazopanib (Arm A);Intermittent pazopanib (Arm B)
12 Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study Recruiting NCT02973997 Phase 2 Lenvatinib
13 Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma Terminated NCT00095693 Phase 2 sorafenib tosylate
14 Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Children and Adolescent Subjects With Advanced BRAF V600-Mutation Positive Solid Tumors Active, not recruiting NCT01677741 Phase 1 Dabrafenib
15 Differences Protein Expression in Papillary Thyroid Carcinoma Unknown status NCT02814032
16 Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma Unknown status NCT01417442 Early Phase 1
17 99mTechnetium-MIBI SPECT-CT for Pre-operative Evaluation of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma; A Pilot Study Unknown status NCT00984191
18 Clinical Investigations on Cytokin-Gradients in Hypo/Euthyroid Patients. Evaluation of Expression of Different Pro-and Anti-Inflammatory Cyto-/Chemokines in Skin Wounds After Surgery of Benign Goitres (Struma Multinodosa) or Malignant Diseases of Thyroid Gland (Papillary Thyroid Carcinoma) in Correlation to the Status of Wound Healing of the Neck Wound Unknown status NCT00929318
19 Does Robotic Assistance Significantly Reduce Postoperative Distress and Patient Complaints About Cosmetic Outcomes After Thyroid Surgery? A Preliminary Report. Unknown status NCT01075269
20 Comparative Analysis Between A Bipolar Vessel Sealing and Cutting Device and the Tie and Suture Technique in Thyroidectomy: A Two Institution Randomized Clinical Trial Unknown status NCT02140476
21 The Effectiveness of Prophylactic Selective Lateral Neck Dissection in Papillary Thyroid Carcinoma Patients With Central Neck Metastasis Completed NCT01103557
22 Prognostic Significance of Fine-Needle Aspiration Cytology Features in Papillary Thyroid Carcinoma Completed NCT00459459
23 Immunohistochemical Detection of the BRAFV600E Mutation on Cytological Specimen in PTC Completed NCT02561533
24 Assessment of Serum Leptin Levels in Females With Papillary Thyroid Carcinoma, Benign Thyroid Nodules, and Normal Controls Completed NCT01659385
25 Comparative Study of Surgical Completeness After Robotic Thyroidectomy Versus Conventional Open Thyroidectomy Completed NCT01354639
26 APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS. Completed NCT02323724
27 A Comparative Study of Robotic Thyroidectomy Using Transaxillary Approach Versus Conventional Open Thyroidectomy : Postoperative Body Image Change and Cosmetic Satisfaction Completed NCT01311089
28 Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436 Completed NCT01534897 GSK2118436
29 Sentinel Node Investigation in Patients With Highly Differentiated Papillary Thyroid Carcinoma and in Patients With Thyroid Neoplasia of Unclear Malignant Potential Completed NCT01089335
30 Optimal Measurement of Thyroglobulin Measurement Following Thyroidectomy Completed NCT02347683
31 Is the Thyroglobulin Measurement Under Thyroxine of Prognostic Value Before rhTSH-Aided Radioiodine Ablation in Differentiated Thyroid Carcinoma? Completed NCT00439127
32 The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma Recruiting NCT02418390
33 A Strategy to Search for Genes Predisposing to Papillary Carcinoma of the Thyroid When Mutated Recruiting NCT02776969
34 Evaluation of Accuracy of One-Step Nucleic Acid Amplification (OSNA) in Diagnosis of Lymph Node Metastases of Papillary Thyroid Carcinoma Recruiting NCT03889769
35 From the Endoscope to the Robot, the Initial Experience of Robotic Thyroidectomy is Summarized Recruiting NCT03454477
36 Active Surveillance of Papillary Thyroid Microcarcinoma Recruiting NCT02609685
37 Clinical Validation of ThyroidPrint: A Gene Expression Signature for Diagnosis of Indeterminate Thyroid Nodules Recruiting NCT03309631
38 Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging in Detecting Metastatic Central Lymph Nodes in Patients With Papillary Thyroid Cancer Recruiting NCT03830242
39 Prospective Study for the Dissection of Lymph Node Posterior to Right Recurrent Laryngeal Nerve for Papillary Thyroid Carcinoma Not yet recruiting NCT03813706
40 Central Cervical Dissection for Clinical Node Negative Papillary Thyroid Carcinoma: a Prospective Study Not yet recruiting NCT03813173
41 A Prospective Randomized Trial Comparing Ultrasound-guided High Intensity Focused Ultrasound (HIFU) Ablation With Active Surveillance (AS) in the Management of Low-risk Papillary Thyroid Microcarcinoma (PTMC) Suspended NCT03327636
42 Central Compartment Neck Dissection Total Thyroidectomy: a Randomized Controlled Trial Terminated NCT01106443

Search NIH Clinical Center for Thyroid Gland Papillary Carcinoma

Genetic Tests for Thyroid Gland Papillary Carcinoma

Anatomical Context for Thyroid Gland Papillary Carcinoma

MalaCards organs/tissues related to Thyroid Gland Papillary Carcinoma:

41
Thyroid, Lymph Node, Breast, Lung, Bone, Testes, Endothelial

Publications for Thyroid Gland Papillary Carcinoma

Articles related to Thyroid Gland Papillary Carcinoma:

(show top 50) (show all 6645)
# Title Authors PMID Year
1
Silencing of long noncoding RNA RP11-476D10.1 enhances apoptosis and autophagy while inhibiting proliferation of papillary thyroid carcinoma cells via microRNA-138-5p-dependent inhibition of LRRK2. 38
31102261 2019
2
The use of The Bethesda System for Reporting Thyroid Cytopathology in a Chinese population: An analysis of 13 351 specimens. 38
31074206 2019
3
Clear Cell Variant of Papillary Thyroid Carcinoma With Associated Anaplastic Thyroid Carcinoma: Description of an Extraordinary Case. 38
30931661 2019
4
Cadmium as main endocrine disruptor in papillary thyroid carcinoma and the significance of Cd/Se ratio for thyroid tissue pathophysiology. 38
31345357 2019
5
The impact of completion thyroidectomy followed by radioactive iodine ablation for patients with lymph node recurrence of papillary thyroid carcinoma. 38
31128851 2019
6
Simultaneous tracheal and esophageal reconstruction for thyroid cancer involving trachea and esophagus using a free bipaddled posterior tibial artery perforator flap. 38
31240807 2019
7
Ultrasound characteristics of thyroid nodules facilitate interpretation of the malignant risk of Bethesda system III/IV thyroid nodules and inform therapeutic schedule. 38
31211509 2019
8
Benign thyroid nodules in pediatric patients: determining best practices for repeat ultrasound evaluations. 38
31271555 2019
9
Active Surveillance for Small Papillary Thyroid Cancer: A Systematic Review and Meta-Analysis. 38
31368412 2019
10
Subcategorisation of AUS/FLUS thyroid lesions as per the 2017 Bethesda System for Reporting Thyroid Cytopathology: a retrospective study from a tertiary care centre analysing risk of malignancy (ROM) of the different subcategories. 38
31375535 2019
11
Digital image-assisted quantitative nuclear analysis improves diagnostic accuracy of thyroid fine-needle aspiration cytology. 38
31150162 2019
12
Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. 38
31319771 2019
13
Increased Incidental Thyroid Cancer in Patients With Subclinical Chronic Lymphocytic Thyroiditis. 38
31415932 2019
14
Papillary Thyroid Cancers with Focal Tall Cell Change are as Aggressive as Tall Cell Variants and Should Not be Considered as Low-Risk Disease. 38
31115855 2019
15
Characterization of activating mutations of the <i>MEK1</i> gene in papillary thyroid carcinomas. 38
31407636 2019
16
Lymph node metastasis in suprasternal space in pathological node-positive papillary thyroid carcinoma. 38
31395292 2019
17
Novel TG-FGFR1 and TRIM33-NTRK1 transcript fusions in papillary thyroid carcinoma. 38
30664823 2019
18
Recurrent Papillary Thyroid Carcinoma to the Cervical Lymph Nodes: Outcomes of Compartment-Oriented Lymph Node Resection. 38
31372725 2019
19
MicroRNA-363-3p suppresses anoikis resistance in human papillary thyroid carcinoma via targeting integrin alpha 6. 38
31257410 2019
20
N-glycan profiling of papillary thyroid carcinoma tissues by MALDI-TOF-MS. 38
31400301 2019
21
Squamous cell carcinoma of the lung and pulmonary metastasis of papillary thyroid carcinoma: a case report. 38
31422769 2019
22
Overexpression of TRIM26 suppresses the proliferation, metastasis, and glycolysis in papillary thyroid carcinoma cells. 38
30927273 2019
23
Prognostic significance of DNMT3A alterations in Middle Eastern papillary thyroid carcinoma. 38
31280122 2019
24
[Clinicopathologic implications of multifocal papillary thyroid carcinoma on poor prognostic outcomes: a propensity score matching analysis]. 38
31434412 2019
25
Efficacy of hemithyroidectomy in papillary thyroid carcinoma with minimal extrathyroidal extension. 38
31414221 2019
26
Mortality risk of nonoperative papillary thyroid carcinoma: a corollary for active surveillance. 38
31407637 2019
27
Postoperative Unstimulated Thyroglobulin for the Decision to Use Radioactive Iodine in Patients with Low- or Intermediate-Risk Papillary Thyroid Carcinoma. 38
31407180 2019
28
MiR-548c-3p suppressed the progression of papillary thyroid carcinoma via inhibition of the HIF1α-mediated VEGF signaling pathway. 38
31378898 2019
29
"Teardrop," "comet," and "bowling-pin" cells in a hobnail variant of papillary thyroid carcinoma fine needle aspirate. 38
30989800 2019
30
Significance and management of incidentally diagnosed metastatic papillary thyroid carcinoma in cervical lymph nodes in neck dissection specimens. 38
31390117 2019
31
Efficacy and safety of lenvatinib in an elderly patient with metastatic papillary thyroid carcinoma and cardiological comorbidity: a case report. 38
31393171 2019
32
PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA. 38
31013158 2019
33
FOXE1 supports the tumor promotion of Gli2 on papillary thyroid carcinoma by the Wnt/β-catenin pathway. 38
30793770 2019
34
Utility of Activated Carbon Nanoparticle (CNP) During total Thyroidectomy for Clinically Nodal Positive Papillary Thyroid Carcinoma (PTC). 38
31399795 2019
35
Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status. 38
30896061 2019
36
Preoperative serum VEGF-C but not VEGF-A level is correlated with lateral neck metastasis in papillary thyroid carcinoma. 38
30843635 2019
37
Successful in vitro fertilization pregnancy and delivery after a fertility-sparing laparoscopic operation in a patient with a papillary thyroid carcinoma arising from a mature cystic teratoma. 38
31401818 2019
38
MicroRNA-524-5p suppresses the progression of papillary thyroid carcinoma cells via targeting on FOXE1 and ITGA3 in cell autophagy and cycling pathways. 38
30941771 2019
39
Factors affecting the approaches and complications of surgery in childhood papillary thyroid carcinomas. 38
31395293 2019
40
Novel design of NIR-triggered plasmonic nanodots capped mesoporous silica nanoparticles loaded with natural capsaicin to inhibition of metastasis of human papillary thyroid carcinoma B-CPAP cells in thyroid cancer chemo-photothermal therapy. 38
31279897 2019
41
Peptide Profile Differences of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features, Encapsulated Follicular Variant, and Classical Papillary Thyroid Carcinoma: An Application of Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging. 38
31064269 2019
42
Role of MDM2 309T>G (rs2279744) and I/D (rs3730485) polymorphisms and haplotypes in risk of papillary thyroid carcinoma, tumor stage, tumor size, and early onset of tumor: A case control study. 38
30548972 2019
43
The use of fluorescence lifetime technology in benign and malignant thyroid tissues. 38
31290382 2019
44
Gene Expression Patterns Unveil New Insights in Papillary Thyroid Cancer. 38
31430969 2019
45
Long-term outcome of rare oncocytic papillary (Hürthle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy. 38
31410542 2019
46
GLIS rearrangements in thyroid nodules: A key to preoperative diagnosis of hyalinizing trabecular tumor. 38
31373774 2019
47
Clinical Analysis of Pediatric Thyroid Cancer: A Single Medical Institution Experience of 18 Years. 38
31375033 2019
48
Sevoflurane inhibits the progression of PTC by downregulating miR-155. 38
31378899 2019
49
Gasless transoral robotic thyroidectomy using the DaVinci SP system: Feasibility, safety, and operative technique. 38
31345381 2019
50
Predicting human disease-associated circRNAs based on locality-constrained linear coding. 38
31394170 2019

Variations for Thyroid Gland Papillary Carcinoma

Cosmic variations for Thyroid Gland Papillary Carcinoma:

9 (show top 50) (show all 1180)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6961574 ZFHX3 thyroid,NS,carcinoma,papillary carcinoma c.5539C>T p.Q1847* 16:72797143-72797143 15
2 COSM7339522 ZBTB2 thyroid,NS,carcinoma,papillary carcinoma c.1012C>G p.P338A 6:151366054-151366054 15
3 COSM7339681 XPO1 thyroid,NS,carcinoma,papillary carcinoma c.1801C>G p.Q601E 2:61492121-61492121 15
4 COSM7340098 XPO1 thyroid,NS,carcinoma,papillary carcinoma c.994G>T p.E332* 2:61495508-61495508 15
5 COSM7339812 WT1 thyroid,NS,carcinoma,papillary carcinoma c.494C>G p.S165W 11:32428568-32428568 15
6 COSM6954354 VTCN1 thyroid,NS,carcinoma,papillary carcinoma c.399C>G p.I133M 1:117156620-117156620 15
7 COSM17721 VHL thyroid,NS,carcinoma,papillary carcinoma c.241C>T p.P81S 3:10142088-10142088 15
8 COSM26416 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1867G>T p.A623S 14:81143925-81143925 15
9 COSM26497 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1915C>T p.P639S 14:81143973-81143973 15
10 COSM26449 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1358T>C p.M453T 14:81143416-81143416 15
11 COSM26417 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1868C>T p.A623V 14:81143926-81143926 15
12 COSM26419 TSHR thyroid,NS,carcinoma,papillary carcinoma c.1897G>T p.D633Y 14:81143955-81143955 15
13 COSM7340068 TSHR thyroid,NS,carcinoma,papillary carcinoma c.572C>T p.S191L 14:81096665-81096665 15
14 COSM7339928 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4760G>A p.C1587Y 16:2086290-2086290 15
15 COSM6918838 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4468G>C p.E1490Q 16:2084690-2084690 15
16 COSM7340474 TSC2 thyroid,NS,carcinoma,papillary carcinoma c.4433A>T p.D1478V 16:2084655-2084655 15
17 COSM7340359 TRRAP thyroid,NS,carcinoma,papillary carcinoma c.7672A>C p.T2558P 7:98971853-98971853 15
18 COSM7340196 TP53BP1 thyroid,NS,carcinoma,papillary carcinoma c.910G>T p.E304* 15:43477623-43477623 15
19 COSM7340198 TP53BP1 thyroid,NS,carcinoma,papillary carcinoma c.5465G>T p.G1822V 15:43409017-43409017 15
20 COSM10771 TP53 thyroid,NS,carcinoma,papillary carcinoma c.749C>T p.P250L 17:7674214-7674214 15
21 COSM10654 TP53 thyroid,NS,carcinoma,papillary carcinoma c.637C>T p.R213* 17:7674894-7674894 15
22 COSM10659 TP53 thyroid,NS,carcinoma,papillary carcinoma c.817C>T p.R273C 17:7673803-7673803 15
23 COSM10867 TP53 thyroid,NS,carcinoma,papillary carcinoma c.797G>A p.G266E 17:7673823-7673823 15
24 COSM10646 TP53 thyroid,NS,carcinoma,papillary carcinoma c.725G>A p.C242Y 17:7674238-7674238 15
25 COSM10726 TP53 thyroid,NS,carcinoma,papillary carcinoma c.856G>A p.E286K 17:7673764-7673764 15
26 COSM11196 TP53 thyroid,NS,carcinoma,papillary carcinoma c.734G>T p.G245V 17:7674229-7674229 15
27 COSM43951 TP53 thyroid,NS,carcinoma,papillary carcinoma c.643A>G p.S215G 17:7674888-7674888 15
28 COSM10648 TP53 thyroid,NS,carcinoma,papillary carcinoma c.524G>A p.R175H 17:7675088-7675088 15
29 COSM43723 TP53 thyroid,NS,carcinoma,papillary carcinoma c.398T>C p.M133T 17:7675214-7675214 15
30 COSM10662 TP53 thyroid,NS,carcinoma,papillary carcinoma c.743G>A p.R248Q 17:7674220-7674220 15
31 COSM10758 TP53 thyroid,NS,carcinoma,papillary carcinoma c.659A>G p.Y220C 17:7674872-7674872 15
32 COSM5444226 TP53 thyroid,NS,carcinoma,papillary carcinoma c.96+1G>C p.? 17:7676381-7676381 15
33 COSM44225 TP53 thyroid,NS,carcinoma,papillary carcinoma c.859G>A p.E287K 17:7673761-7673761 15
34 COSM10739 TP53 thyroid,NS,carcinoma,papillary carcinoma c.481G>A p.A161T 17:7675131-7675131 15
35 COSM44922 TP53 thyroid,NS,carcinoma,papillary carcinoma c.670G>T p.E224* 17:7674861-7674861 15
36 COSM44338 TP53 thyroid,NS,carcinoma,papillary carcinoma c.845G>A p.R282Q 17:7673775-7673775 15
37 COSM10812 TP53 thyroid,NS,carcinoma,papillary carcinoma c.722C>T p.S241F 17:7674241-7674241 15
38 COSM44101 TP53 thyroid,NS,carcinoma,papillary carcinoma c.417G>C p.K139N 17:7675195-7675195 15
39 COSM10660 TP53 thyroid,NS,carcinoma,papillary carcinoma c.818G>A p.R273H 17:7673802-7673802 15
40 COSM10667 TP53 thyroid,NS,carcinoma,papillary carcinoma c.646G>A p.V216M 17:7674885-7674885 15
41 COSM11183 TP53 thyroid,NS,carcinoma,papillary carcinoma c.799C>T p.R267W 17:7673821-7673821 15
42 COSM43801 TP53 thyroid,NS,carcinoma,papillary carcinoma c.716A>C p.N239T 17:7674247-7674247 15
43 COSM43980 TP53 thyroid,NS,carcinoma,papillary carcinoma c.691A>G p.T231A 17:7674272-7674272 15
44 COSM10863 TP53 thyroid,NS,carcinoma,papillary carcinoma c.833C>T p.P278L 17:7673787-7673787 15
45 COSM11114 TP53 thyroid,NS,carcinoma,papillary carcinoma c.528C>G p.C176W 17:7675084-7675084 15
46 COSM44988 TP53 thyroid,NS,carcinoma,papillary carcinoma c.374C>T p.T125M 17:7675995-7675995 15
47 COSM10705 TP53 thyroid,NS,carcinoma,papillary carcinoma c.586C>T p.R196* 17:7674945-7674945 15
48 COSM10731 TP53 thyroid,NS,carcinoma,papillary carcinoma c.707A>G p.Y236C 17:7674256-7674256 15
49 COSM10735 TP53 thyroid,NS,carcinoma,papillary carcinoma c.638G>A p.R213Q 17:7674893-7674893 15
50 COSM10738 TP53 thyroid,NS,carcinoma,papillary carcinoma c.542G>A p.R181H 17:7675070-7675070 15

Expression for Thyroid Gland Papillary Carcinoma

Search GEO for disease gene expression data for Thyroid Gland Papillary Carcinoma.

Pathways for Thyroid Gland Papillary Carcinoma

GO Terms for Thyroid Gland Papillary Carcinoma

Biological processes related to Thyroid Gland Papillary Carcinoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.97 RET PTCH1 PAX8 NKX2-1 NCOA4
2 gene silencing by miRNA GO:0035195 9.96 MIR509-1 MIR222 MIR221 MIR146B MIR146A
3 positive regulation of gene expression GO:0010628 9.92 RET NKX2-1 MIR509-1 MIR146A BRAF
4 animal organ morphogenesis GO:0009887 9.77 PTCH1 NKX2-1 BRAF
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.72 MIR222 MIR221 BRAF
6 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.65 MIR221 MIR146B MIR146A
7 negative regulation of smoothened signaling pathway GO:0045879 9.6 PTCH2 PTCH1
8 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.58 MIR222 MIR221
9 cell fate determination GO:0001709 9.57 PTCH2 PTCH1
10 positive regulation of epidermal cell differentiation GO:0045606 9.54 PTCH2 PTCH1
11 negative regulation by host of viral genome replication GO:0044828 9.51 MIR222 MIR221
12 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.49 MIR222 MIR221
13 negative regulation of cell adhesion molecule production GO:0060354 9.46 MIR222 MIR221
14 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.43 MIR222 MIR221
15 epidermal cell fate specification GO:0009957 9.4 PTCH2 PTCH1
16 thyroid-stimulating hormone signaling pathway GO:0038194 9.37 TSHR PAX8
17 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.32 MIR222 MIR221
18 positive regulation of Schwann cell migration GO:1900149 9.26 MIR222 MIR221
19 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.16 MIR222 MIR221
20 positive regulation of axon regeneration GO:0048680 9.13 MIR222 MIR221 BRAF
21 thyroid gland development GO:0030878 8.92 TG PAX8 NKX2-1 BRAF

Molecular functions related to Thyroid Gland Papillary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 smoothened binding GO:0005119 9.32 PTCH2 PTCH1
2 hedgehog receptor activity GO:0008158 9.26 PTCH2 PTCH1
3 hedgehog family protein binding GO:0097108 9.16 PTCH2 PTCH1
4 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.02 MIR509-1 MIR222 MIR221 MIR146B MIR146A
5 thyroid-stimulating hormone receptor activity GO:0004996 8.96 TSHR PAX8

Sources for Thyroid Gland Papillary Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....